ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that the Company performed regulatory animal studies treating target vessels with its occlusion system - (EOS) device. The procedures had a 100% success rate in terms of safety and effectiveness.

The device demonstrated accurate, predictable and immediate occlusion of the targeted blood vessels. The EOS device has the potential to address the need for occlusion of vessels in a wide variety of peripheral vascular applications.

The study was performed by a group of physicians from the Johns Hopkins University (Baltimore, MD) and the George Washington University (Washington, DC).

"This study paves the way for the Company's planned First in Man studies scheduled to begin in June as the Company continues the planned execution of its targeted 2011 European commercialization of the EOS device," said Dr. Leon Rudakov, President and CTO, ArtVentive Medical Group, Inc. "We are pleased with the continued compounding success that we have experienced and we look forward to the expansion of our family of EOS devices."

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in San Marcos, California, is an innovative, multi-faceted medical device corporation committed to developing, manufacturing and marketing a family of endoluminal occlusion devices (EOS).

ArtVentive Medical Group, Inc., through its proprietary technology has developed unique minimally invasive occlusion devices and procedures bringing the current interventional image guided techniques to a new level of sophistication, resolving significant and unaddressed health issues. The EOS is a catheter based self-expandable device, serving for permanent or temporary (reversible) occlusion of body lumens. The patented revolutionary device will serve in many cases as a safe and reliable alternative to major surgery. ArtVentive's EOS device targets a substantive market demand in several major clinical areas, including women's health, peripheral and neurological vascular disorders in addition to interventional cardiology procedures.

More information about the Company can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release may include "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are based on the beliefs by our management as well as assumptions made by and information currently available to the company. These statements reflect the company's current views with respect to future events and are not guarantees of future performance. These statements may involve risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the said forward-looking statements. These factors include, among other things, the company's periodic reports filed with the Securities and Exchange Commission. You should not put undue reliance on any forward-looking statements. Except as required by law, the company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the company's filings with the Securities and Exchange Commission which are available from the SEC's EDGAR database at www.sec.gov, at various SEC reference facilities in the United States.

ArtVentive Medical Group, Inc.
H.J. (Jim) Graham, CEO
760-471-7700
hjgraham@artventivemedical.com